The NFX Podcast
We believe creating something of true significance starts with seeing things others do not. NFX is a venture firm exclusively focused on pre-seed & seed stage startups.
NFXBio: Deal or Die – A Guide to TechBio Business Development and Strategy
There are two parts to building a bioplatform: you have to focus on the science, then you have to think about the business side. When do you partner? When do you develop your own products? How can you determine the real value of a deal? How do you build a strategic network? What avenues are Founders overlooking right now? These are questions our companies ask us all the time. Today, Head of NFXBio Omri Amirav-Dory, Yael Gruenbaum-Cohen, a venture partner at aMoon Fund, and Peter Nell, former Chief Business Officer and head of Therapeutics at Mammoth Biosciences, are charting a roadmap for successful bioplatform business development.
Key Points
- Business development is crucial and can significantly advance a company, especially in challenging funding times, by utilizing smart, patient, and professional approaches.
- A strong business development leader should be a team player with strategic thinking, excellent communication skills, and adept at both internal and external relationship management.
- For platform companies, the art of business development lies in knowing what to sell and for how much, with every deal having a unique value based on the company's stage, resources, and long-term strategy.
Chapters
| 0:00 | |
| 4:06 | |
| 11:33 | |
| 17:19 | |
| 23:13 | |
| 30:04 | |
| 36:29 | |
| 38:48 | |
| 41:00 | |
| 43:49 |
Transcript
Loading transcript...
- / -